TAIPEI, Taiwan, Jan. 8 /Xinhua-PRNewswire/ -- TaiGen Biotechnology Inc. announced today that the company has started enrollment of patients for the Phase II clinical trial of Nemonoxacin (TG-873870) for the treatment of adult community acquired pneumonia (CAP). The randomized, double-blind, comparative, multi-center study is designed to evaluate the effect of Nemonoxacin in comparison with levofloxacin, the leading quinolone on the market. The study will evaluate both clinical and bacteriological success rates in treating adult patients with CAP.
"The initiation of the Phase II study is an important milestone for TaiGen as we continue to build our product portfolio for treating infectious diseases," stated Dr. Ming-Chu Hsu, President & CEO of TaiGen. "In our early non-clinical studies, Nemonoxacin has demonstrated superior activity against various resistant pathogens, including MRSA, in comparison with otherantibiotics. The incident of MRSA infection is rising worldwide. With its extremely broad-spectrum of activity and good safety profile demonstrated in the phase 1 trials, TaiGen plans to develop the oral Nemonoxacin for multiple indications, including a phase 2 trial to treat diabetic foot infection to be initiated soon." An intravenous formulation of Nemonoxacin is scheduled to enter clinical trials in the spring of 2007.
About TaiGen Biotechnology
TaiGen Biotechnology ( www.taigenbiotech.com ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, cancer and diabetic complications. TaiGen has established a full capacity to conduct new drug research and clinical development in China, US and other countries. The company is building its product pipeline through internal research and in-licensing of late clinical stage products. In addition to the clinical development of Nemonoxacin, the company has pre-clinical drug candidates for treating hepatitis C virus infection, cancer and diabetic related complications including diabetic critical limb ischemia and retinopathy.
TaiGen Contact:
Dr. Stephen Ip
SVP Global Business Development
Tel: +886-2-2790-1861
